Phase 2 × Waldenstrom Macroglobulinemia × Other hematologic neoplasm × Clear all
NCT03333486 2025-07-04

Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer

Roswell Park Cancer Institute

Phase 2 Terminated
31 enrolled 18 charts
NCT00544115 2025-06-10

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

City of Hope Medical Center

Phase 2 Active not recruiting
260 enrolled 13 charts
NCT03246906 2025-06-04

Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

Fred Hutchinson Cancer Center

Phase 2 Terminated
150 enrolled
NCT00004192 2023-12-27

Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma

University of Nebraska

Phase 2 Completed
60 enrolled
NCT01044745 2023-09-06

Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer

University of Nebraska

Phase 2 Terminated
20 enrolled 8 charts
NCT01384513 2022-11-17

A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies

Thomas Jefferson University

Phase 2 Completed
40 enrolled
NCT01261247 2022-05-24

Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Mayo Clinic

Phase 2 Completed
41 enrolled 8 charts
NCT00612716 2020-12-09

Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

Masonic Cancer Center, University of Minnesota

Phase 2 Completed
6 enrolled 16 charts
NCT00003963 2020-08-03

Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell Transplantation

Jonsson Comprehensive Cancer Center

Phase 2 Completed
14 enrolled
NCT00096161 2020-01-31

Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant

Fred Hutchinson Cancer Center

Phase 2 Completed
36 enrolled 13 charts
NCT00040846 2020-01-29

Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies

Fred Hutchinson Cancer Center

Phase 2 Completed
60 enrolled 10 charts
NCT01527045 2020-01-02

Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies

Fred Hutchinson Cancer Center

Phase 2 Completed
47 enrolled 18 charts
NCT01251575 2019-12-09

Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant

Fred Hutchinson Cancer Center

Phase 2 Completed
77 enrolled 10 charts
NCT00105001 2019-10-30

Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Fred Hutchinson Cancer Center

Phase 2 Completed
210 enrolled 15 charts
NCT00436618 2019-10-22

Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment

Mayo Clinic

Phase 2 Completed
277 enrolled 11 charts
NCT00003396 2019-10-17

Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

University of Maryland, Baltimore

Phase 2 Completed
42 enrolled
NCT01529827 2019-09-24

Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Roswell Park Cancer Institute

Phase 2 Completed
94 enrolled 11 charts
NCT01839916 2019-08-07

Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

University of Chicago

Phase 2 Completed
77 enrolled 12 charts
NCT01008462 2019-06-11

Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

Fred Hutchinson Cancer Center

Phase 2 Completed
16 enrolled 15 charts
NCT01116232 2019-03-26

Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation

Barbara Ann Karmanos Cancer Institute

Phase 2 Terminated
4 enrolled 4 charts
NCT01240525 2019-02-12

ProT4

University College, London

Phase 2 Unknown
114 enrolled
NCT01093586 2019-01-23

Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Case Comprehensive Cancer Center

Phase 2 Completed
14 enrolled 22 charts
NCT00621036 2018-11-26

Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma

University of Texas Southwestern Medical Center

Phase 2 Withdrawn
NCT01273766 2018-09-07

Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies

Wake Forest University Health Sciences

Phase 2 Completed
16 enrolled 10 charts
NCT01789255 2018-07-24

Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies

National Cancer Institute (NCI)

Phase 2 Completed
12 enrolled 11 charts
NCT00119392 2018-06-29

Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Fred Hutchinson Cancer Center

Phase 2 Completed
42 enrolled 11 charts
NCT00867529 2018-01-02

Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma

Fred Hutchinson Cancer Center

Phase 2 Completed
63 enrolled 12 charts
NCT01419795 2017-07-27

Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant

Fred Hutchinson Cancer Center

Phase 2 Terminated
3 enrolled 10 charts
NCT00072514 2017-06-29

Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies

Fred Hutchinson Cancer Center

Phase 2 Completed
55 enrolled 6 charts
NCT00719849 2017-06-14

Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease

Fred Hutchinson Cancer Center

Phase 2 Terminated
13 enrolled 24 charts
NCT00118352 2017-05-30

Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Fred Hutchinson Cancer Center

Phase 2 Completed
12 enrolled 10 charts
NCT01110135 2017-05-24

Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma

University of Washington

Phase 2 Completed
43 enrolled 5 charts